TY - JOUR
T1 - Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs
AU - Bratcher, Denise F.
AU - Bourne, Nigel
AU - Bravo, Fernando J.
AU - Schleiss, Mark R.
AU - Slaoui, Moncef
AU - Myers, Martin G.
AU - Bernstein, David I.
PY - 1995/10
Y1 - 1995/10
N2 - Cytomegalovirus (CMV) is the most common congenital viral infection, but little is known about the protective immune mechanisms. The guinea pig (gp) model of congenital CMV was used to evaluate the effects of passive antibody given to pregnant dams on pup survival. Dams received three doses of high-titer gpCMV or control antibody on days −3, −1, and +7, or + 1, +3, and +7, in relation to gpCMV challenge. gpCMV was inoculated in the late second to early third trimester at three different doses. Compared with controls, gpCMV antibody begun before gpCMV challenge significantly increased pup survival from 14% to 52%, 21% to 84%, and 51% to 77%, respectively, for the three challenge doses. gpCMV antibody started after viral challenge increased pup survival after only the lowest challenge dose (51% to 81%). Antibody did not protect against CMV infection of the pups. CMV antibody appeared to improve survival in congenital CMV infection but did not affect vertical transmission.
AB - Cytomegalovirus (CMV) is the most common congenital viral infection, but little is known about the protective immune mechanisms. The guinea pig (gp) model of congenital CMV was used to evaluate the effects of passive antibody given to pregnant dams on pup survival. Dams received three doses of high-titer gpCMV or control antibody on days −3, −1, and +7, or + 1, +3, and +7, in relation to gpCMV challenge. gpCMV was inoculated in the late second to early third trimester at three different doses. Compared with controls, gpCMV antibody begun before gpCMV challenge significantly increased pup survival from 14% to 52%, 21% to 84%, and 51% to 77%, respectively, for the three challenge doses. gpCMV antibody started after viral challenge increased pup survival after only the lowest challenge dose (51% to 81%). Antibody did not protect against CMV infection of the pups. CMV antibody appeared to improve survival in congenital CMV infection but did not affect vertical transmission.
UR - http://www.scopus.com/inward/record.url?scp=0029120768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029120768&partnerID=8YFLogxK
U2 - 10.1093/infdis/172.4.944
DO - 10.1093/infdis/172.4.944
M3 - Article
C2 - 7561214
AN - SCOPUS:0029120768
SN - 0022-1899
VL - 172
SP - 944
EP - 950
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -